Financials Square Pharmaceuticals PLC.

Equities

End-of-day quote Dhaka S.E. Other stock markets 06:00:00 2024-05-19 pm EDT			5-day change	1st Jan Change
206.3 ^BDT	-0.15%		-2.32%	-1.90%

Apr. 30	Square Pharmaceuticals PLC. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
Feb. 01	Square Pharmaceuticals PLC. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI

Fiscal Period: June	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	208,535	145,631	191,030	192,094	185,977	182,875	-	-
Enterprise Value (EV) ¹	208,535	113,067	147,770	140,679	137,870	182,875	182,875	182,875
P/E ratio	-	10.4 x	12 x	10.6 x	9.8 x	8.78 x	7.51 x	6.65 x
Yield	1.7%	2.86%	2.78%	4.61%	5%	4.97%	5.45%	6.06%
Capitalization / Revenue	4.74 x	3.17 x	3.77 x	3.34 x	2.96 x	2.58 x	2.3 x	2.06 x
EV / Revenue	4.74 x	3.17 x	3.77 x	3.34 x	2.96 x	2.58 x	2.3 x	2.06 x
EV / EBITDA	12.9 x	8.72 x	10.6 x	9.5 x	9.01 x	8.19 x	7.16 x	6.38 x
EV / FCF	20.2 x	16.7 x	26.4 x	19.8 x	32.5 x	13.1 x	11 x	11.4 x
FCF Yield	4.96%	5.99%	3.78%	5.06%	3.08%	7.66%	9.06%	8.75%
Price to Book	2.87 x	1.79 x	2.1 x	1.86 x	1.61 x	1.44 x	1.3 x	1.16 x
Nbr of stocks (in thousands)	886,451	886,451	886,451	886,451	886,451	886,451	-	-
Reference price ²	235.2	164.3	215.5	216.7	209.8	206.3	206.3	206.3
Announcement Date	11/27/19	12/1/20	11/25/21	12/4/22	11/22/23	-	-	-

¹BDT in Million²BDT

Estimates

Fiscal Period: June	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	44,034	45,876	50,703	57,598	62,748	71,018	79,678	88,579
EBITDA ¹	16,170	16,701	18,009	20,218	20,651	22,316	25,542	28,656
EBIT ¹	14,143	14,731	16,126	18,383	18,341	20,430	23,584	26,522
Operating Margin	32.12%	32.11%	31.81%	31.92%	29.23%	28.77%	29.6%	29.94%
Earnings before Tax (EBT) ¹	-	16,998	18,756	21,025	21,099	24,978	27,839	31,302
Net income ¹	-	13,354	14,743	16,417	18,858	21,317	24,371	27,527
Net margin	-	29.11%	29.08%	28.5%	30.05%	30.02%	30.59%	31.08%
EPS ²	-	15.82	17.99	20.51	21.41	23.50	27.48	31.04
Free Cash Flow ¹	10,343	8,719	7,223	9,713	5,721	14,004	16,563	15,996
FCF margin	23.49%	19%	14.25%	16.86%	9.12%	19.72%	20.79%	18.06%
FCF Conversion (EBITDA)	63.96%	52.21%	40.11%	48.04%	27.71%	62.75%	64.85%	55.82%
FCF Conversion (Net income)	-	65.29%	48.99%	59.16%	30.34%	65.69%	67.96%	58.11%
Dividend per Share ²	4.000	4.700	6.000	10.00	10.50	10.25	11.25	12.50
Announcement Date	11/27/19	12/1/20	11/25/21	12/4/22	11/22/23	-	-	-

¹BDT in Million²BDT

Estimates

Fiscal Period: June	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-	-
Net Cash position	-	32,564	43,260	51,415	48,107	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow ¹	10,343	8,719	7,223	9,713	5,721	14,004	16,563	15,996
ROE (net income / shareholders' equity)	20.1%	18.4%	17.5%	18.7%	17.1%	17.2%	17.8%	18%
ROA (Net income/ Total Assets)	19%	17.3%	16.6%	17.7%	16.1%	16.3%	16.9%	17.2%
Assets ¹	-	76,983	88,636	92,778	116,787	131,182	144,492	160,351
Book Value Per Share ²	81.90	91.60	103.0	117.0	130.0	144.0	159.0	177.0
Cash Flow per Share ²	-	-	-	-	9.640	26.50	29.60	33.30
Capex	2,049	2,042	3,798	6,052	-	-	-	-
Capex / Sales	4.65%	4.45%	7.49%	10.51%	-	-	-	-
Announcement Date	11/27/19	12/1/20	11/25/21	12/4/22	11/22/23	-	-	-

¹BDT in Million²BDT

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

206.3 BDT

Average target price

321.8 BDT

Spread / Average Target

+55.96%